Project Grant R61HL171747
Award Date
9/5/24
Completion Date
7/31/26
Dollars Obligated
$564K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University (M5QFLTCTSQN6)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
Novelmed Therapeutics, Inc. was awarded a $1,599,495 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services. The grant falls under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. Novelmed will use the funding to develop a novel disease-modifying treatment for paroxysmal nocturnal hemoglobinuria (PNH). The company's lead drug candidate selectively inhibits the alternative pathway of...
This Project Grant award for $395,314, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program, aims to define the innate immune cell profile associated with the development of inhibitory antibodies against Factor VIII (FVIII) in individuals with hemophilia A. The central goals are to: 1) Characterize the cytokine microenvironment and role of conventional dendritic cells (cDC2) in activating CD4+ T cells and inducing...
This $306,656 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of new biotechnological approaches to expeditiously synthesize heparin-like anticoagulants using engineered microbial cellular factories. The project aims to provide an alternative, reliable drug production process for heparin, a critical medicine used to treat thrombosis and other clotting disorders, which face...
This federal Project Grant award of $1,371,242 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a multi-year study to identify genetic and environmental factors underlying the high incidence of factor VIII inhibitor development in hemophilia A patients of Mexican ancestry. The research project aims to enroll and characterize a cohort of 200 severe hemophilia A patients with Mexican ancestry, leveraging an...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on characterizing the role of the alternative complement pathway in the pathogenesis of acute chest syndrome (ACS) in sickle cell disease (SCD). The key objectives are to: 1) define the mechanisms by which complement contributes to the development of ACS using novel preclinical models, microfluidics, and in vitro assays; 2) characterize...
The federal Project Grant award F31HL178296, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to elucidate the interplay between DDX41 and CUX1 mutations in hematopoiesis using zebrafish and human induced pluripotent stem cells (iPSCs). The $161,922 award, with a performance period from July 2025 to March 2028, aims to characterize the impact of these co-occurring mutations on hematopoietic stem...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $146,922 to Albert Einstein College of Medicine to conduct research on the genotype-environmental interactions that drive hematopoietic stem and progenitor cell (HSPC) dysfunction. The research aims to investigate how aging and inflammation contribute to the development of myelodysplastic syndromes (MDS), a type of myeloid...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
This Project Grant award, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), will fund a collaborative research program to investigate fundamental questions surrounding anti-ABO(H) antibodies and their target antigens on red blood cells. The $5,187,690 award, with a performance period from August 1, 2024 to July 31, 2029, will support three distinct research projects and complementary core facilities led by a multidisciplinary team of...
This $633,720 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to unveil the prevalence and biological roles of protein arginylation in cardiovascular development and disease. The key goals are to: 1) develop a proteomics platform to comprehensively profile arginylation sites in cardiac cells and tissues, 2) elucidate the impacts of arginylation on epigenetic mechanisms and cardiac cell functions, and 3)...